Jonathan Baell
Jonathan Baell (né Ball) is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco. Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS), the director of the Australian Translational Medicinal Chemistry Facility and a Chief Investigator at the ARC Centre for Fragment-Based Design. He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board. His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases. Provided by Wikipedia-
1by Yaqing Jiao, Sarah Preston, Hongjian Song, Abdul Jabbar, Yuxiu Liu, Jonathan Baell, Andreas Hofmann, Dana Hutchinson, Tao Wang, Anson V. Koehler, Gillian M. Fisher, Katherine T. Andrews, Benoît Laleu, Michael J. Palmer, Jeremy N. Burrows, Timothy N. C. Wells, Qingmin Wang, Robin B. GasserGet full text
Published 2017-05-01
Article